Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study

NCT02489773 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2019-11-21

Study results available
· View outcomes & findings →

Summary

To confirm that Lucica ® Glycated Albumin-L is useful for the intermediate term (preceding 2-3 weeks) monitoring of glycemic control in patients with diabetes.

Conditions

Sponsors & Collaborators

  • Asahi Kasei Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Hideji Hiraoka, M.S. · Diagnostics Department, Asahi Kasei Pharma

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02489773 on ClinicalTrials.gov